Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors Clinical Trials in Cincinnati, Ohio

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors